A nationwide population-based study on prescribing trends published in the Annals of Internal Medicine found a significant increase in new users of GLP-1 receptor agonists who don’t have a diagnosis of type 2 diabetes. The proportion of new GLP-1 users with type 2 diabetes decreased from nearly 90% to about 70% from 2019 to 2023, according to a separate analysis of the findings in MedPage Today. Meanwhile, new users tend to be those prescribed the …
Read More